Biopharma M&A + Investment During a Downturn
Applying Modern Market Intelligence and Innovative Strategies
A panel discussion with:
Matthias Muellenbeck, SVP, Head of Global Business Development & Alliance Management, Merck KGaA
Stephanie Sirota, Partner & Chief Business Officer, RTW Investments
Ed Kivell, VP of Global Strategic Accounts EMEA/APAC, AlphaSense
Michael Margolis, Senior Managing Director, Co-Head of Healthcare Investment Banking, Oppenheimer & Co.
After a difficult 2022 for the life sciences industry, as we enter 2023 what are expectations for the investment, deal-making and M&A landscape? How best can the industry innovate and apply modern market intelligence and new strategies for the year ahead?
Factors influencing Biopharma M&A and investment activity during economic downturns
Applying modern market intelligence in biopharma M&A and investing
How have data sources for deal flow evolved in recent years?
Practising modern market intelligence
Identifying and completing investment and M&A deals
How winners innovate - doubling down in a downturn
In partnership with Alphasense
Staying up to date on clinical trial pipelines, evolving markets, disease areas, and BD&L opportunities is highly time-consuming and fragmented. AlphaSense ensures you find the information you need faster and before it’s on anyone else’s radar.
www.alpha-sense.com
The LSX channel features sessions from LSX events, where our mission is to connect senior #biotech, #medtech & #healthtech executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.
Subscribe to our channel for more videos.
Follow us on Twitter: / lsxleaders
Visit us at www.lsxleaders.com